Introduction {#tca12572-sec-0005}
============

Lung cancer remains the leading cause of cancer‐related death worldwide. Non‐small cell lung cancer (NSCLC) subtypes, including lung adenocarcinoma (LAC), account for approximately 85% of all lung cancers.[1](#tca12572-bib-0001){ref-type="ref"} Although tremendous efforts have been devoted to improving treatment procedures through novel chemotherapies combined with targeted agents, the overall survival rate remains low.[2](#tca12572-bib-0002){ref-type="ref"} Transferrin receptor (TfR) is a 190 kDa glycoprotein expressed on the cytoplasmic membrane of a wide variety of cells.[3](#tca12572-bib-0003){ref-type="ref"}, [4](#tca12572-bib-0004){ref-type="ref"} One of its key roles is controlling cell growth through iron uptake. However, there is evidence that TfR has many other biological roles in addition to its primary function of facilitating iron transport and metabolism, such as its profound effect on mammalian cell growth and productivity.[5](#tca12572-bib-0005){ref-type="ref"}, [6](#tca12572-bib-0006){ref-type="ref"} TfR expression is normally restricted to a limited number of sites in humans, including basal keratinocytes of the epidermis; islet cells of the pancreas; and parenchymal cells of the liver, testis, and pituitary gland.[7](#tca12572-bib-0007){ref-type="ref"}, [8](#tca12572-bib-0008){ref-type="ref"}, [9](#tca12572-bib-0009){ref-type="ref"} In healthy lung tissue, airway and alveolar epithelia and bronchial glands do not express TfR.[7](#tca12572-bib-0007){ref-type="ref"} However, TfR is expressed in most lung cancers and the presence of TfR in NSCLCs is an indicator of poor prognosis in certain groups of patients.[7](#tca12572-bib-0007){ref-type="ref"}, [10](#tca12572-bib-0010){ref-type="ref"} In the present study we blocked cell surface TfR with the aim of inhibiting LAC cell growth in vitro, and investigated the associated molecular mechanisms to find a potential therapeutic target in human LAC.

Methods {#tca12572-sec-0006}
=======

Cell culture {#tca12572-sec-0007}
------------

Normal human bronchial epithelial (HBE) cells and LAC cell lines (H1299 and A549) were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). These cells were cultured in Dulbecco\'s Modified Eagle medium (DMEM; Corning, Christiansburg, VA, USA) supplemented with 10% fetal bovine serum and a 1% antibiotic mixture (100 U/mL penicillin G and 100 μg/mL streptomycin sulfate; Beyotime Biotechnology, Shanghai, China), and incubated at 37°C in a humidified 5% CO~2~ atmosphere. Upon reaching 90% confluence, the cells were dissociated using 0.25% trypsin (HyClone, Shanghai, China) and subcultured.

Immunofluorescence staining {#tca12572-sec-0008}
---------------------------

HBE, H1299, and A549 cells were harvested from flasks and washed with phosphate buffered saline. Each sample contained 100 000 cells and was resuspended in 10 μL of a 50‐fold‐diluted human Fc receptor binding inhibitor (eBioscience, San Diego, CA, USA) for 5 minutes on ice, followed by staining with 2 μL of either a phycoerythrin‐labeled human TfR antibody (OKT9, eBioscience) or a PE‐labeled mouse immunoglobulin G1 (IgG1) isotype control antibody (P3.6.2.8.1, eBioscience) for 30 minutes at 4°C in the dark. The cells were then washed three times and resuspended in 400 μL of ice‐cold phosphate buffered saline/2 mM ethylene‐diamine‐tetraacetic acid. The median fluorescence intensity (MFI) of the samples was quantified using an Attune cytometer with a 488 nm excitation laser and a 574/26 nm emission filter (Life Technologies, Waltham, MA, USA). Cell populations were gated according to the forward and side scattering channel, and 10 000 events were collected. Data analysis was performed using Attune cytometer software (Life Technologies). Experiments were conducted three times.

RNA interference {#tca12572-sec-0009}
----------------

A transfection mix consisting of 1 μL of RNAiMAX (Invitrogen, Carlsbad, CA, USA) and 12 nM TfR siRNA (Silencer Select small interfering RNAs \[siRNAs\] 107 046, 107 047, and 107 048) purchased from Ambion in Opti‐Mem (Invitrogen) was mixed with suspended cells for 20 minutes at room temperature prior to seeding at 5000 cells per well in 96‐well plates. The medium was changed to DMEM after 24 hours. Total cellular RNA was extracted using 1× Nucleic Acid Purification Lysis Solution (Applied Biosystems, Foster City, CA, USA).

Antibody blocking of transferrin receptor (TfR) {#tca12572-sec-0010}
-----------------------------------------------

An antihuman TfR monoclonal antibody (M‐A712) used for blocking was purchased from BD Biosciences Pharmingen (San Diego, CA, USA).[11](#tca12572-bib-0011){ref-type="ref"} Cells were incubated with 25 μg/mL isotype control or the TfR antibodies.[11](#tca12572-bib-0011){ref-type="ref"} After 24, 48, 72, and 96 hours, cellular RNA was harvested using 1× Nucleic Acid Purification Lysis Solution (Applied Biosystems).

Proliferation assay {#tca12572-sec-0011}
-------------------

Cell proliferation was measured using colorimetric 3‐(4,5‐dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐sulfophenyl)‐2H‐tetrazolium, inner salt (MTS) assay (CellTiter 96 AQueous One Solution Cell Proliferation Assay; Promega, Madison, WI, USA). H1299 cells (2 × 10^4^ cells/mL) were incubated with 25 μg/mL anti‐TfR antibody in complete medium at 37°C and 5% CO~2~. The proliferation assay was performed at 24, 48, 72, and 96 hours after antibody blocking. The MTS assay was performed as previously described.[12](#tca12572-bib-0012){ref-type="ref"} Each experiment was performed three times, and the typical results are shown.

Microarray analysis {#tca12572-sec-0012}
-------------------

Cellular RNA from H1299 cells was extracted using TRIzol (Invitrogen), and quality control was performed as directed by the Affymetrix expression technical manual. RNA (50 ng) was used to produce biotin‐labeled complementary RNA, which was hybridized to the Affymetrix GeneChip Human Genome U133 Plus 2.0 array (Affymetrix, Inc., Santa Clara, CA, USA). Array washing, scanning, and probe quantification protocols were performed according to the manufacturer\'s instructions using Affymetrix GeneChip Operating Software (GCOS) (<http://www.affymetrix.com>).[13](#tca12572-bib-0013){ref-type="ref"} Genes that displayed two‐fold or greater expression changes between the control and antibody blocking groups were filtered using the Student\'s *t*‐test with a significance threshold of *P* \< 0.05. Hierarchical clustering with average linkage was performed only for the differentially expressed genes (DEGs), using Cluster 3.0. The cluster data were visualized using Java TreeView software (Microsoft, Redmond, WA, USA). Gene ontology (GO) and pathway analysis of the DEGs were performed using CapitalBio Molecule Annotation System (MAS) version 3.0 (<http://bioinfo.capitalbio.com/mas3/>), which can integrate multiple biological databases with the MAS core database. The information required for pathway analysis was obtained from three pathway databases, the Kyoto Encyclopedia of Genes and Genomes (KEGG), Biocarta, and GenMAPP, which are the major authoritative pathway databases.[12](#tca12572-bib-0012){ref-type="ref"}

Real‐time PCR {#tca12572-sec-0013}
-------------

Total RNA was extracted and then reverse transcribed into complementary DNA (cDNA) using a PrimeScript RT reagent kit (TaKaRa Biotechnology, Dalian, China) according to the manufacturer\'s instructions. The PCR reactions were carried out in a 50‐μL reaction mixture with a 96‐well format using SYBR Premix Ex Taq II (TaKaRa Biotechnology) in a 7300 real‐time PCR system (Applied Biosystems). Three biological replicates were created for each gene. The results were normalized to glyceraldehyde 3‐phosphate dehydrogenase (GAPDH), and the amount of each transcript was calculated using the formula 2^−(ΔCT(target\ gene) − ΔCT(GAPDH))^, where the cycle threshold value indicates the time at which the fluorescence rose appreciably above the background fluorescence.[14](#tca12572-bib-0014){ref-type="ref"} The following primers were used: TfR, 5′‐CAGCCCAGCAGAAGCATT‐3′ and 5′‐CCAAGAACCGCTTTATCCAG‐3′;KRAS, 5′‐GACTGAATATAAACTTGTGGTAGTTGGACCT‐3′ and 5′‐TCCTCTTGACCTGCTGTGTCG‐3′; and GAPDH, 5′‐CAAGATCATCAGCAATGCCT‐3′ and 5′‐AGGGATGATGTTCTGGAGAG‐3′.

Western blot {#tca12572-sec-0014}
------------

Total cellular proteins were isolated from cultured cells using lysis buffer and assayed by Western blot according to previously described procedures.[15](#tca12572-bib-0015){ref-type="ref"} Proteins were detected according to the manufacturer\'s instructions. Briefly, equal amounts of protein were denatured, electrophoresed (SDS‐PAGE gel kit, Beyotime), and transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membranes were then incubated overnight with primary antibody, washed with tris‐buffered saline plus tween 20, and then incubated with a second antibody. The proteins were detected using ECL chemiluminescence (Millipore). The primary antibodies were mouse anti‐TfR (1:1000, M‐A712, BD Pharmingen), and mouse anti‐*KRAS* (1:1000) and mouse anti‐GAPDH (1:1000; Cell Signaling Technology, Danvers, MA, USA). The secondary antibody was horseradish peroxidase‐conjugated rabbit anti‐mouse IgG (1:10 000; Cell Signaling Technology).

Statistical analysis {#tca12572-sec-0015}
--------------------

The results are presented as the mean ± standard deviation. Proliferation assay and real‐time PCR data were analyzed using paired *t*‐tests. Statistical analysis was conducted using SPSS version 13.0 statistical software (SPSS Inc., Chicago, IL, USA). A two‐tailed *P* value of \< 0.05 was considered statistically significant.

Results {#tca12572-sec-0016}
=======

TfR expression {#tca12572-sec-0017}
--------------

The TfR expression levels in the normal HBE cells and lung adenocarcinoma cell lines (H1299 and A549) were measured via flow cytometry. The cells were immunostained with a fluorescent‐labeled anti‐TfR antibody or an isotype control antibody. As shown in Figure [1](#tca12572-fig-0001){ref-type="fig"}a, the MFI across three cell lines was unchanged when stained with the isotype antibody, indicating that little fluorescence was caused by non‐specific antibody binding. By contrast, H1299 and A549 cells demonstrated a significantly higher MFI after being stained with the anti‐TfR antibody compared to the HBE cells and the MFI in H1299 cells was higher than in A549 cells (Fig [1](#tca12572-fig-0001){ref-type="fig"}a). Similarly, H1299 and A549 cells demonstrated markedly higher levels of TfR protein expression compared to the HBE cell line, as determined by Western blot analysis (Fig [1](#tca12572-fig-0001){ref-type="fig"}b). Additionally, the TfR protein expression level in H1299 cells was higher than in A549 cells (Fig [1](#tca12572-fig-0001){ref-type="fig"}b). Therefore, the H1299 cells were considered the TfR overexpressing cell model for our study.

![Transferrin receptor (TfR) protein expression in human bronchial epithelial (HBE), H1299, and A549 cells and effect of TfR small interfering RNA (siRNA) in H1299 cells. (**a**) HBE, H1299, and A549 cells were immunostained with the anti‐TfR antibody, which binds to TfR, and by an isotype antibody, which served as a non‐specific binding control. Median fluorescence intensity (MFI) was quantified via flow cytometry. Data are representative of at least three independent experiments. (Data points indicate mean ± standard deviation; \**P* \< 0.05). (**b**) Western blot analysis of TfR protein expression in HBE, H1299, and A549 cells. Glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) was used as a loading control. (**c**) Effect of TfR siRNA on the TfR messenger RNA level in H1299 cells, determined by real‐time PCR. The messenger RNA levels were significantly decreased following the siRNA‐mediated knockdown of TfR compared to the negative control (*P* = 0.004) and mock‐transfected (*P* = 0.009) cells. (**d**) TfR protein levels in the TfR‐knockdown H1299 cells, as determined by Western blot. GAPDH was used as a loading control. Mock group: untreated; negative control group: transfected with control siRNA; TfR siRNA group: transfected with a TfR‐specific siRNA.](TCA-9-253-g001){#tca12572-fig-0001}

TfR knockdown using small interfering RNA inhibits H1299 cell proliferation {#tca12572-sec-0018}
---------------------------------------------------------------------------

As an initial experiment to determine whether TfR is functionally involved in H1299 cell proliferation, we assessed the effect of TfR knockdown. H1299 cells were transfected with an irrelevant control siRNA or a TfR‐specific siRNA 24 hours after cells were seeded. Real‐time PCR confirmed the knockdown efficiency of the TfR‐siRNA. TfR messenger RNA (mRNA) expression was significantly decreased (*P* = 0.004 vs. the negative control; *P* = 0.009 vs. the mock transfection) (Fig [1](#tca12572-fig-0001){ref-type="fig"}c) 96 hours after transfection in H1299 cells following the silencing of TfR by its specific siRNA, resulting in downregulation of the TfR protein (Fig [1](#tca12572-fig-0001){ref-type="fig"}d).

After transfection, the cells were incubated in complete medium for an additional 24, 48, 72, or 96 hours. MTS assay results showed that transfection with the TfR siRNA resulted in significantly decreased cell viability compared to the negative control at each time point (Fig [2](#tca12572-fig-0002){ref-type="fig"}a).

![The effect of transferrin receptor (TfR) small interfering RNA (siRNA) or TfR antibody blocking on cell proliferation and Heat map of the 100 overlapping genes. Effects of (**a**) TfR siRNA and (**b**) blocking cell surface TfR on cell proliferation, determined by MTS assay. \**P* \< 0.05 versus the negative control; \*\**P* \< 0.01 versus the negative control. OD, optical density. (**c**) Hierarchical clustering of 100 messenger RNA expression patterns in the anti‐TfR versus the negative control group. Red/green indicates an increase/decrease in gene expression, relative to the universal mean for each gene.](TCA-9-253-g002){#tca12572-fig-0002}

Blocking cell surface TfR inhibits H1299 cell proliferation {#tca12572-sec-0019}
-----------------------------------------------------------

Because TfR knockdown appeared to inhibit H1299 cell proliferation, we investigated whether blocking surface TfR had a similar effect. Initially, we performed blocking experiments in which antibodies were added to the cells 24 hours after cell seeding. H1299 cells were incubated with irrelevant mouse IgG negative control or the anti‐TfR. The cells were then incubated in complete medium for an additional 24, 48, 72, or 96 hours. MTS assay results showed that blocking TfR also resulted in significantly decreased cell viability compared to the negative control at each time point (Fig [2](#tca12572-fig-0002){ref-type="fig"}b).

Differentially expressed genes {#tca12572-sec-0020}
------------------------------

To investigate the molecular mechanisms of blocking TfR inhibiting cell proliferation, cDNA microarray analysis was utilized to identify regulated gene expression 72 hours after TfR was blocked. A total of six microarrays were used, and three biological replicates were created for each condition (anti‐TfR vs. the negative control group). Transcriptome analysis between the negative control and anti‐TfR groups revealed that 100 DEGs with a cut‐off threshold of 2 (*P* \< 0.05) showed a correct hybridization signal on the six arrays. Of the 100 differentially expressed mRNAs between the negative control and anti‐TfR groups, 4 (4.0%) were highly expressed in the anti‐TfR groups and 96 (96.0%) were highly expressed in the negative control group. Hierarchical clustering is presented in Figure [2](#tca12572-fig-0002){ref-type="fig"}c.

GO analysis of the 100 DEGs revealed that blocking TfR regulates genes that are involved in cell proliferation, apoptosis, cell cycle, transcription, translation, biosynthetic processes, metabolic processes, protein and nucleic acid binding, proteolysis, signal transduction, and ion transmembrane transport regulation, among others (Table [S1](#tca12572-supitem-0001){ref-type="supplementary-material"}). Table [1](#tca12572-tbl-0001){ref-type="table-wrap"} shows the DEGs associated with cell proliferation, apoptosis, the cell cycle, and transcription. Pathway analysis was successfully performed to associate differentially regulated genes with known specific biological pathways using the CapitalBio MAS platform. This pathway analysis revealed the central regulatory role played by *KRAS* (Fig [3](#tca12572-fig-0003){ref-type="fig"}).

###### 

Genes associated with proliferation, apoptosis, cell cycle, and transcription

  Function        Gene ID                                                                      Gene title                          Gene symbol   Fold change (Anti‐TfR vs. control groups)   *P*
  --------------- ---------------------------------------------------------------------------- ----------------------------------- ------------- ------------------------------------------- --------
  Proliferation   8678                                                                         Beclin 1, autophagy related         BECN1         0.4585                                      0.0006
  1296            Collagen, type VIII, alpha 2                                                 COL8A2                              0.3775        0.0437                                      
  2100            Estrogen receptor 2 (ER beta)                                                ESR2                                0.3821        0.0053                                      
  *3845*          *Kirsten rat sarcoma viral oncogene homolog*                                 *KRAS*                              *0.4682*      *0.0053*                                    
  5697            Peptide YY                                                                   PYY                                 0.4656        0.0424                                      
  9481            Solute carrier family 25, member 27                                          SLC25A27                            0.3886        0.0392                                      
  Apoptosis       23 604                                                                       Death‐associated protein kinase 2   DAPK2         0.4978                                      0.0199
  Cell cycle      3537                                                                         Cytoskeleton associated protein 2   CKAP2         0.4244                                      0.0160
  54 737          M‐phase phosphoprotein 8                                                     MPHOSPH8                            2.1859        0.0297                                      
  4772            Nuclear factor of activated T‐cells, cytoplasmic, calcineurin‐dependent 1    NFATC1                              0.4236        0.0018                                      
  126 520         Polo‐like kinase 5                                                           PLK5                                0.4779        0.0004                                      
  5933            Retinoblastoma‐like 1                                                        RBL1                                0.4931        0.0361                                      
  6714            SRC proto‐oncogene, non‐receptor tyrosine kinase                             SRC                                 0.3405        0.0157                                      
  Transcription   1386                                                                         Activating transcription factor 2   ATF2          0.4413                                      0.0174
  2303            Forkhead box C2 (MFH‐1, mesenchyme forkhead 1)                               FOXC2                               0.4735        0.0075                                      
  136 259         Kruppel‐like factor 14                                                       KLF14                               0.4533        0.0070                                      
  7849            Paired box 8                                                                 PAX8                                0.4337        0.0344                                      
  862             Runt‐related transcription factor 1; translocated to, 1 (cyclin D‐related)   RUNX1T1                             0.3855        0.0130                                      
  147 949         Zinc finger protein 583                                                      ZNF583                              0.4020        0.0107                                      

![The differentially expressed genes were analyzed using CapitalBio MAS version 3.0. The blue lines indicate that the information regarding the gene relationships was obtained from the KEGG database, and the green lines indicate that the information was obtained from the GenMAPP database. Pathway analysis revealed that *KRAS* (colored red) has a greater number of connections with other genes.](TCA-9-253-g003){#tca12572-fig-0003}

Validation of microarray data by real‐time PCR and Western blot {#tca12572-sec-0021}
---------------------------------------------------------------

To validate the microarray results, we performed real‐time PCR and Western blot analysis on the negative control and anti‐TfR H1299 cells. *KRAS* was relevant to the biological function of proliferation and could partially illuminate the molecular mechanisms of cell proliferation induced by blocking TfR (Table [1](#tca12572-tbl-0001){ref-type="table-wrap"}). Because the pathway analysis showed that *KRAS* plays a central regulatory role after TfR is blocked (Fig [3](#tca12572-fig-0003){ref-type="fig"}), *KRAS* was selected for further analysis. To observe the dynamic trend of the *KRAS* gene after blocking TfR, we performed real‐time PCR on control and anti‐TfR H1299 cells 24, 48, 72, and 96 hours after blocking TfR. The results were analyzed by comparing relative gene expression using the 2^−ΔCt^ method.[14](#tca12572-bib-0014){ref-type="ref"} *KRAS* mRNA expression levels in the anti‐TfR group were significantly lower than in the negative control from 24 to 96 hours after blocking (*P \< 0.05*) (Fig [4](#tca12572-fig-0004){ref-type="fig"}a). We then determined whether blocking TfR affected the expression of endogenous *KRAS* at the translational level. As shown in Figure [4](#tca12572-fig-0004){ref-type="fig"}b, Western blot analysis revealed that the level of KRAS protein expression in the anti‐TfR group was significantly inhibited compared to that in the negative control group 96 hours after blocking.

![(**a**) Validation of KRAS messenger RNA (mRNA) expression using real‐time PCR. Comparison of the dynamic trend of mRNA expression of KRAS in the negative control and anti‐TfR groups 24, 48, 72, and 96 hours after TfR was blocked. Data analysis using the 2^−ΔCt^ method shows the relative expression levels of individual genes when normalized to the internal control, glyceraldehyde 3‐phosphate dehydrogenase (GAPDH). (**b**) Validation of protein expression using Western blot. KRAS protein levels were examined in the negative control and anti‐TfR groups 96 hours after TfR was blocked. GAPDH was used as a loading control. Negative control group: H1299 cells were incubated with an irrelevant mouse immunoglobulin G (IgG) antibody; anti‐TfR group: cells were incubated with an anti‐TfR antibody.](TCA-9-253-g004){#tca12572-fig-0004}

Discussion {#tca12572-sec-0022}
==========

Transferrin receptor is a membrane protein expressed at low levels in most cells and can bind to the iron transport glycoprotein Tf, which consequently triggers fast internalization.[16](#tca12572-bib-0016){ref-type="ref"}, [17](#tca12572-bib-0017){ref-type="ref"}, [18](#tca12572-bib-0018){ref-type="ref"}, [19](#tca12572-bib-0019){ref-type="ref"} Our investigation of the functions and properties of TfR in iron transport indicate that TfR plays a greater biological role than previously thought.[5](#tca12572-bib-0005){ref-type="ref"}, [20](#tca12572-bib-0020){ref-type="ref"}, [21](#tca12572-bib-0021){ref-type="ref"} Xie *et al.* reported that H1299 cells demonstrate significantly higher TfR expression compared to A549 and H460 cells.[22](#tca12572-bib-0022){ref-type="ref"} Therefore, we chose to use A549 and H1299 cell lines to locate a TfR overexpressing cell. In this study, we observed upregulated protein levels of cellular TfR in lung adenocarcinoma H1299 cells (Fig [1](#tca12572-fig-0001){ref-type="fig"}a,b). After siRNA knockdown or TfR blocking, we observed inhibition of H1299 cell proliferation, demonstrating that TfR plays a role in LAC growth (Fig [2](#tca12572-fig-0002){ref-type="fig"}a,b). Mechanistic studies suggest that blocking TfR may exert an effect by inhibiting *KRAS* (Figs [3](#tca12572-fig-0003){ref-type="fig"}, [4](#tca12572-fig-0004){ref-type="fig"}).

Transferrin receptor plays a crucial role in the cellular uptake of iron, and cellular iron deficiency arrests cell growth, leading to cell death.[23](#tca12572-bib-0023){ref-type="ref"} TfR is expressed more abundantly in malignant tissues than in normal tissues because cancer cells require copious amounts of iron to maintain their high proliferation rates.[24](#tca12572-bib-0024){ref-type="ref"} Therefore, TfR is an attractive target for immunotherapy and for the delivery of cytotoxic agents because of its increased expression in malignant compared to normal cells.[25](#tca12572-bib-0025){ref-type="ref"}, [26](#tca12572-bib-0026){ref-type="ref"}, [27](#tca12572-bib-0027){ref-type="ref"} TfR is expressed in most lung cancers, and the presence of TfR in NSCLCs may be an indicator of poor prognosis in certain groups of patients.[7](#tca12572-bib-0007){ref-type="ref"} Herein, we showed that TfR itself could possibly be a therapeutic target for LAC, with the anti‐human TfR‐specific antibody described in this manuscript. The mechanism behind the selective cancer cell killing ability of the anti‐TfR antibody has not yet been elucidated. However, it is speculated that cancer cells require more iron than normal cells to sustain their abnormally rapid growth rates, thus reducing the intracellular iron concentration by preventing TfR‐mediated cellular iron uptake may cause growth inhibition and cell death in cancer cells.[28](#tca12572-bib-0028){ref-type="ref"}, [29](#tca12572-bib-0029){ref-type="ref"} In LAC, the anti‐TfR antibody is suspected to block the internalization of transferrin into cancer cells, and the resulting transferrin deficiency might block the cell cycle and/or induce apoptotic cell death because of the potentially abnormal transferrin requirements of cancer cells. In addition, Tf, which is the ligand for TfR, can act as a growth factor in most cells in tissue culture, as a neurotrophic factor during neural stem cell development, and as an angiogenic factor to promote endothelial cell migration.[5](#tca12572-bib-0005){ref-type="ref"} Blocking TfR results in the inhibition of these Tf functions. In this study, we observed that the proliferation of H1299 cells was significantly inhibited after siRNA knockdown or after TfR was blocked (Fig [2](#tca12572-fig-0002){ref-type="fig"}a,b). These results indicate that TfR is potentially a therapeutic target for lung adenocarcinoma. In addition, the small‐molecule iron transport inhibitor ferristatin/NSC306711 promotes TfR degradation, which may be used in LAC therapy in the future.[17](#tca12572-bib-0017){ref-type="ref"}, [30](#tca12572-bib-0030){ref-type="ref"}

As previously reported, TfR expression is significantly upregulated in cancer, increasing several 100‐fold in various tumor cell lines and malignant tissues.[26](#tca12572-bib-0026){ref-type="ref"} Although the receptor has an established physiological function within the tissue, its aberrant stimulation and overexpression in cancer could act as an attractive targeting molecule for cancer therapy. A number of studies have shown the capacity of anti‐transferrin receptor antibodies to limit cell growth in cultured, normal, and malignant cells.[26](#tca12572-bib-0026){ref-type="ref"} However, no relevant study has reported whether blocking TfR will have any adverse effects on other normal tissues or organs. This issue requires further exploration in future research.

Complementary DNA microarray analysis showed that 100 genes were altered more than two‐fold after TfR was blocked. We grouped the 100 regulated genes into functional categories that included cell proliferation, apoptosis, cell cycle, transcription, translation, biosynthetic processes, metabolic processes, protein and nucleic acid binding, proteolysis, signal transduction, and ion transmembrane transport regulation, among others (Table [S1](#tca12572-supitem-0001){ref-type="supplementary-material"}). Pathway analysis showed that *KRAS* plays a central regulatory role, and was thus selected for further analysis (Fig [3](#tca12572-fig-0003){ref-type="fig"}). Real‐time PCR and Western blot analysis validated the array findings for the *KRAS* gene (Fig [4](#tca12572-fig-0004){ref-type="fig"}).

*KRAS* is an oncogene that functions as a critical molecular switch for various biological processes, including cell proliferation, survival, differentiation, and death.[31](#tca12572-bib-0031){ref-type="ref"}, [32](#tca12572-bib-0032){ref-type="ref"}, [33](#tca12572-bib-0033){ref-type="ref"} *KRAS* is associated with increased cell growth and differentiation in many cancers.[34](#tca12572-bib-0034){ref-type="ref"}, [35](#tca12572-bib-0035){ref-type="ref"}, [36](#tca12572-bib-0036){ref-type="ref"} In addition, Yoon *et al.* showed that *KRAS* plays a key role in signal transduction in NSCLC.[37](#tca12572-bib-0037){ref-type="ref"} Activating *KRAS* mutations are present in more than 80% of all NSCLCs.[38](#tca12572-bib-0038){ref-type="ref"}, [39](#tca12572-bib-0039){ref-type="ref"} This mutation leads to constant receptor phosphorylation and the activation of downstream cascade pathways (such as the RAS, PI3K, and AKT signaling pathways) that are important for the regulation of cell proliferation and growth.[40](#tca12572-bib-0040){ref-type="ref"} It has been shown that activating *KRAS* mutations lead to subsequent activation of the RAS--RAF pathway.[40](#tca12572-bib-0040){ref-type="ref"} Inhibiting *KRAS* results in the inhibition of cancer cell proliferation and growth; however, direct *KRAS* targeting has proven to be difficult.[41](#tca12572-bib-0041){ref-type="ref"}, [42](#tca12572-bib-0042){ref-type="ref"}, [43](#tca12572-bib-0043){ref-type="ref"} Some strategies for interrupting oncogenic *KRAS* signals, such as inhibiting post‐translational modification and Ras protein membrane association, have been employed, but unfortunately no clinical benefits using these methods have been determined.[41](#tca12572-bib-0041){ref-type="ref"} In this study, we observed that blocking TfR resulted in the downregulation of *KRAS* mRNA and protein levels in lung adenocarcinoma H1299 cells (Figs [3](#tca12572-fig-0003){ref-type="fig"}, [4](#tca12572-fig-0004){ref-type="fig"}). Our results suggest a new method for blocking the oncogenic *KRAS* signal by targeting TfR in LAC. The mechanisms of TfR suppression of *KRAS* expression are unknown. TfR acts as a growth factor in most cells in tissue culture,[5](#tca12572-bib-0005){ref-type="ref"}, [6](#tca12572-bib-0006){ref-type="ref"} thus we hypothesize that this may be related to the non‐facilitating iron transport of TfR and intend to conduct further research.

In conclusion, we found that blocking TfR could significantly inhibit LAC proliferation by targeting the oncogene *KRAS.* These results indicate that blocking TfR may suppress LAC progression and imply its potential application in LAC therapy. We plan to initiate a clinical trial to determine the usefulness and benefits of TfR as a therapeutic target for LAC.
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